Recombinant human interleukin-15 (rhIL-15)

BIOLOGICAL2 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Adult T-Cell Lymphoma/LeukemiaBrain TumorsMycosis FungoidesNeuroblastomaPediatric CancersSarcomaSezary SyndromeSolid Tumors

Phase 1

NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors

CompletedNCT01875601

National Cancer Institute (NCI)Brain Tumors, Neuroblastoma, Pediatric Cancers +2

Start: 2013-06-11End: 2015-09-08Updated: 2026-02-17

Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome

CompletedNCT04185220

National Cancer Institute (NCI)Adult T-Cell Lymphoma/Leukemia, Mycosis Fungoides, Sezary Syndrome

Start: 2020-02-26End: 2022-05-18Updated: 2023-01-04

Related Papers

A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies

Blood Neoplasia2024-11-02

621 A phase I study of autologous activated NK cells ± rhIL15 in children and young adults with refractory solid tumors

Regular and Young Investigator Award Abstracts2023-10-311 citations

Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies

Blood Advances2022-04-2719 citations

Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies

Journal for ImmunoTherapy of Cancer2021-04-0143 citations

IL-15 in the Combination Immunotherapy of Cancer.

2020-05-19183 citations